The stock of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is a huge mover today! The stock increased 0.93% or $0.03 on September 30, hitting $3.26. About 133,101 shares traded hands. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has risen 15.77% since February 26, 2016 and is uptrending. It has outperformed by 5.35% the S&P500.
The move comes after 6 months positive chart setup for the $149.05M company. It was reported on Oct, 1 by Barchart.com. We have $6.72 PT which if reached, will make NASDAQ:NYMX worth $157.99M more.
According to Zacks Investment Research, “Nymox Pharmaceutical Corporation is engaged in the research and development of drugs and diagnostic products. The company offers products such as AlzheimAlert, NicAlert and TobacAlert tests. It markets its products primarily in the United States, Canada, and Europe. Nymox Pharmaceutical Corporation is based in St Laurent, Canada.”
More notable recent Nymox Pharmaceutical Corporation (NASDAQ:NYMX) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on February 06, 2011, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on August 10, 2016, Quotes.Wsj.com published: “News Nymox Pharmaceutical Corp.NYMX” on February 12, 2011. More interesting news about Nymox Pharmaceutical Corporation (NASDAQ:NYMX) were released by: Prnewswire.com and their article: “Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block …” published on August 11, 2016 as well as Schaeffersresearch.com‘s news article titled: “Nymox Pharmaceutical Corporation (NYMX) Puts Popular Despite Drug Data” with publication date: August 29, 2016.
NYMX Company Profile
Nymox Pharmaceutical Corporation, incorporated on May 30, 1995, is a biopharmaceutical company. The Firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Firm operates through the research and development of products for the aging population segment. The Firm markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Firm also has a range of patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Firm also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. The Company’s subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.